Experimental drug trial offers hope for rare blood disease patients
NCT ID NCT02523040
Summary
This study is testing whether the chemotherapy drug lenalidomide can help control three rare disorders where the body makes too many immune cells. Researchers are enrolling 12 adults with Langerhans cell histiocytosis, Erdheim-Chester disease, or histiocytic sarcoma who need systemic treatment. The goal is to see if this already-approved cancer drug can shrink tumors and control disease progression in these rare conditions.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LANGERHANS CELL HISTIOCYTOSIS (LCH) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Dana-Farber Cancer Institute
Boston, Massachusetts, 02115, United States
Conditions
Explore the condition pages connected to this study.